Description: Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial. It is also developing AB154, an anti-T-cell immunoreceptor with Ig and ITIM domains antibody, which is in Phase I trial as monotherapy; and AB680, a small-molecule inhibitor of CD73 that is in Phase I healthy volunteer study. The company has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate AB122, an anti-PD-1 antibody. Arcus Biosciences, Inc. was founded in 2015 and is headquartered in Hayward, California.
Home Page: www.arcusbio.com
RCUS Technical Analysis
3928 Point Eden Way
Hayward,
CA
94545
United States
Phone:
510 694 6200
Officers
| Name | Title |
|---|---|
| Dr. Terry J. Rosen Ph.D. | Co-Founder, Chairman & CEO |
| Dr. Juan Carlos Jaen Ph.D. | Co-Founder, Pres & Director |
| Mr. Robert C. Goeltz II | Principal Financial & Accounting Officer and CFO |
| Ms. Jennifer A. Jarrett M.B.A. | COO & Director |
| Ms. Carolyn C. Tang J.D. | Gen. Counsel & Corp. Sec. |
| Dr. K. Christopher Garcia Ph.D. | Co-Founder & Member of Scientific Advisory Board |
| Dr. Stephen Young Ph.D. | Sr. VP of Technology & Quantitative Biology |
| Dr. Jonathan Yingling Ph.D. | Chief Scientific Officer |
| Ms. Katherine Bock | VP of Investor Relations & Corp. Strategy |
| Holli Kolkey | VP of Corp. Communications |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 16.3964 |
| Price-to-Book MRQ: | 3.1494 |
| Price-to-Sales TTM: | 5.1858 |
| IPO Date: | 2018-03-15 |
| Fiscal Year End: | December |
| Full Time Employees: | 366 |